TP53 and lung cancer: Interestingly, sensitivity to proteasome inhibition was partially dependent on the p53 status of breast [35] and lung cancer in vitro [36], but bortezomib-induced apoptosis and/or chemosensitization were p53 independent in prostate [13], multiple myeloma [15], and colon cancer cells [30].